Albertsons Opioid Trial in Washington Ends: State Asks for $2.2 Billion in Abatement

The Albertsons opioid trial in Washington ended in mid-September 2026 with the State asking King County Superior Court Judge Janet Helson to order roughly $2.2 billion in abatement against Albertsons Companies and its Safeway subsidiary, the grocer's apportioned share of a statewide remediation plan the State's expert priced at about $44.4 billion. There was no jury: the case was tried to the bench over roughly two months, and Judge Helson will now issue findings of fact and conclusions of law that decide both whether the pharmacy chain is liable and, if it is, what it pays.

That makes this the last major opioid trial standing, and the only one in which a state is litigating against a national pharmacy chain that has already settled with almost everyone else. Albertsons announced a $774 million national opioid settlement framework on 14 April 2026, covering substantially all state, local and tribal claims against it and payable over nine years. Washington was not in it. The State had opted out, as it did with the distributors in 2021, and went to trial instead.

What did Washington ask for in the Albertsons opioid trial?

Washington asked for abatement, not damages. Law360 reported on 17 September 2026 that at the close of the two-month bench trial the State's lawyers told Judge Helson that Albertsons and Safeway should pay approximately $2.2 billion toward the cost of remediating the opioid crisis in Washington. The number is not a compensatory award to identified victims and it is not Punitive Damages. It is an equitable remedy: the cost of the programs the State says are needed to undo a public nuisance the defendants helped create and maintain.

Jeff Gaddy of Levin Papantonio Rafferty, one of the outside lawyers representing the State, put the causation argument to the court in a line that will follow the case: "Albertsons showed up to a campfire with gallons of gasoline, poured it out, and the state is still burning."

Albertsons' position at trial was that its pharmacies met or exceeded the applicable standard of care and that, whatever the scale of the crisis, the company was not a substantial factor in causing it. That framing matters because it targets the weakest joint in every abatement case: the link between one dispenser's conduct and a statewide harm with many contributors.

How many opioid pills did Albertsons dispense in Washington?

The Attorney General's Office alleges that between 2006 and 2022 Albertsons dispensed more than 641 million prescription opioid pills in Washington, and that the company filled more than 6.5 million prescriptions carrying red flags of diversion that were never resolved. Reporting from the trial put the share of dispensed volume carrying unresolved red flags at most of the total.

The State's case is not limited to dispensing. It also alleges that for a period Albertsons self-distributed opioids to its own stores, and that it failed to report tens of thousands of suspicious orders from its own pharmacies to the Drug Enforcement Administration as federal law requires. That two-sided theory — dispenser duty at the counter, registrant duty in the supply chain — is what let the State reach conduct across nearly two decades rather than a set of individual prescriptions.

The human denominator the State put behind those numbers: more than 26,000 people in Washington have died of an opioid overdose. When the Attorney General's Office first sued Albertsons, Kroger and Rite Aid in King County Superior Court in December 2022, the complaint counted more than 12,000 opioid overdose deaths in the State between 2006 and 2021.

What is the legal theory behind Washington's case against Albertsons?

Two counts survived to trial: public nuisance under Washington's nuisance statutes, and unfair or deceptive practices under the Washington Consumer Protection Act. Washington defines a public nuisance as one affecting the rights of an entire community or neighborhood, and an actionable nuisance as including whatever is injurious to health. The State's pleading fused the two: unfair and deceptive business practices that create a public nuisance across the State.

Before trial, Judge Helson held that Albertsons and Safeway owed a duty, as dispensers of controlled substances, to verify the legitimacy of the opioid prescriptions they filled. That ruling is the load-bearing beam. Without a dispenser duty, the red-flag evidence is atmospheric; with it, every unresolved red flag is a potential breach.

The State also survived the defendants' attempt to end the case before it had to put on a defense. Albertsons moved on 18 August 2026 for judgment as a matter of law on both the public nuisance and Consumer Protection Act claims. On 27 August 2026 Judge Helson denied the motion, holding that a reasonable fact-finder could conclude on the evidence presented that Washington was entitled to relief. In a bench trial that denial carries extra weight, because the judge who decides the motion is the same judge who will weigh the evidence at the end.

How the $44.4 billion abatement plan produces a $2.2 billion demand

The State's abatement case rests on a costed remediation model rather than a damages calculation. Dr. Ted Miller, a health economist and operations research analyst with more than five decades of practice, testified that addressing the harm from prescription opioid misuse in Washington would cost close to $44.4 billion. His plan is organized around four buckets: treatment, harm reduction, primary prevention, and system coordination.

The $2.2 billion the State asked for at closing is Albertsons' and Safeway's apportioned share of that total, not the total itself. Apportionment is the pressure point on appeal. A defendant that dispensed a minority of the opioid volume in a state will argue that a share of a statewide program cost is a damages award wearing equitable clothing, and that the abatement label cannot survive contact with the actual arithmetic.

Washington opioid recovery	Amount	Route	Note
McKesson, Cardinal Health, AmerisourceBergen (2022)	$518 million	Opt-out; settled at the close of evidence after a roughly six-month trial	More than $476 million directed to abatement, paid over 17 years
What the national distributor deal offered Washington	up to $417.9 million	National Global Settlement	The opt-out premium was roughly $100 million
Purdue Pharma	$183 million	Bankruptcy-track resolution	Reported by the Attorney General's Office
McKinsey & Company	$13.5 million	Separate resolution	Reported by the Attorney General's Office
Kroger (2024)	$47.5 million	Settlement of the companion King County case	Filed alongside Albertsons and Rite Aid in December 2022
Albertsons national framework (14 April 2026)	$774 million nationwide	Declined by Washington	Payable over nine years; not an admission of liability
Albertsons — Washington's demand at closing	approximately $2.2 billion	Trial	Share of a $44.4 billion abatement model

Why Washington opted out of the $774 million national settlement

Washington has run the same play three times, and the ledger explains why. In 2021 the State walked away from the national distributor and manufacturer deal, under which it stood to receive up to $417.9 million from McKesson, Cardinal Health and AmerisourceBergen. It tried the case instead, and settled at the close of evidence in May 2022 for up to $518 million, with McKesson paying $197 million and Cardinal and AmerisourceBergen $160.5 million each. More than $476 million of that runs to abatement over 17 years.

The economics of that decision are the whole argument for opt-out state litigation. A national Global Settlement prices a state by population and overdose metrics on a formula negotiated for the median claimant. A state willing to try its own case prices itself by its own evidence, and can hold out for the difference. The risk is symmetrical: a state that loses a bench trial recovers nothing and has forfeited the allocation it declined.

Albertsons' $774 million framework covers substantially all claims by state, local and tribal governments nationally. Albertsons recorded a pre-tax charge of roughly $600 million in the quarter it was announced, producing a reported operating loss of about $480 million, and said the settlement is not an admission of wrongdoing or liability. The company operates roughly 1,713 in-store pharmacies across about 2,244 stores in 35 states and the District of Columbia. Against that footprint, a $2.2 billion single-state judgment would be a different order of exposure from the national deal it declined to extend to Washington.

Does the Ohio public-nuisance ruling reach Washington?

Not directly, and the difference is statutory. In December 2024 the Supreme Court of Ohio held in the certified-question posture of In re National Prescription Opiate Litigation that the Ohio Product Liability Act, as amended in 2007, abrogated common-law public nuisance claims arising from the sale of a product, so Lake and Trumbull Counties could not recover against CVS, Walgreens and Walmart on that theory. The answer put the $650.9 million abatement judgment those counties had won in 2022 in the federal opioid Multidistrict Litigation (MDL) in jeopardy, and commentators read it as effectively terminating the counties' public nuisance claims once the Sixth Circuit applied it.

Washington's case is differently situated in three ways that practitioners should not blur. First, the claim is statutory rather than common-law: Washington pleads its nuisance statutes, not a judge-made tort that a product liability act could be read to displace. Second, the plaintiff is the State exercising sovereign enforcement authority under the Consumer Protection Act, not a county suing for its own budget. Third, the theory is conduct-based — failure to resolve red flags, failure to report suspicious orders — rather than a claim that selling a lawful, federally approved product is itself a nuisance. That distinction is the one Ohio's product liability act was read to foreclose, and it is the one Washington's pleading is built to avoid.

None of which makes the point academic. If Albertsons appeals a loss, the argument that abatement for product sales is a product liability claim in disguise will travel to Division I of the Court of Appeals and, likely, to the Washington Supreme Court.

What happens next, and when will Judge Helson rule?

No ruling date has been set. In a Washington bench trial the court issues written findings of fact and conclusions of law, which on a record of this size typically takes weeks to months rather than days. Either side can then move for reconsideration or for amended findings before the judgment becomes final and the appeal clock starts.

The appellate posture is worth flagging now, because it differs sharply from the jury verdicts that dominate Mass Tort coverage. Findings of fact from a bench trial are reviewed for substantial evidence, a deferential standard; conclusions of law, including whether the conduct proved amounts to a public nuisance and whether a $2.2 billion apportionment is properly equitable, are reviewed de novo. A plaintiff that wins the facts can still lose the remedy.

Date	Event
December 2022	Washington sues Albertsons, Kroger and Rite Aid in King County Superior Court
2024	Kroger settles with Washington for $47.5 million
14 April 2026	Albertsons announces a $774 million national opioid settlement framework; Washington is not a participant
13 July 2026	Bench trial opens before Judge Janet Helson
18 August 2026	Albertsons moves for judgment as a matter of law on the nuisance and Consumer Protection Act claims
27 August 2026	Judge Helson denies the motion; the defense case proceeds
Mid-September 2026	Closing arguments; the State asks for approximately $2.2 billion in abatement
Pending	Findings of fact and conclusions of law

What it means for state AGs, plaintiffs' firms and pharmacy defendants

For state attorneys general. Washington's record is now three data points, not one: a $518 million opt-out result against the distributors, a $47.5 million companion settlement with Kroger, and a $2.2 billion ask against the last defendant standing. Offices weighing whether to join the next national framework have a concrete comparator for what declining is worth, and a concrete picture of the cost — a six-month trial in 2021-22 and a two-month trial in 2026, both tried with outside counsel.

For plaintiffs' firms on AG mandates. These cases are staffed on Contingency Fee arrangements negotiated with state law offices and governed by state procurement rules, not by the common benefit structures familiar from an MDL. The trial-level economics are brutal: a two-month bench trial with dozens of experts, funded on the prospect of an equitable award that may be reduced or vacated on de novo review of the remedy. Firms modeling the next wave should price the appellate tail, not just the trial.

For pharmacy and retail defendants. A national settlement framework no longer buys peace where a state has opted out, and the holdout state will be the one with the strongest evidence, because that is why it held out. Dispensing records, red-flag resolution documentation and suspicious order monitoring files are the exhibits that decide these cases, and they are generated years before anyone contemplates litigation.

For subdivision and tribal counsel. Washington's abatement model prices statewide remediation across four program areas. Whatever Judge Helson does with it, the model itself becomes a template — and a target — for the next round of costed abatement demands, and defendants will now have a trial record with which to attack it.

Frequently asked questions

What did Washington ask for in the Albertsons opioid trial?

Washington asked Judge Janet Helson to order Albertsons and Safeway to pay roughly $2.2 billion in abatement, their apportioned share of a statewide opioid remediation plan the State's expert costed at about $44.4 billion.

Who is the judge in the Albertsons opioid trial and when will she rule?

King County Superior Court Judge Janet Helson tried the case without a jury and will decide both liability and remedy in written findings of fact and conclusions of law; no ruling date has been announced.

Why did Washington opt out of the $774 million Albertsons opioid settlement?

Washington has consistently declined national opioid settlements in favor of trying its own cases, a strategy that in 2022 produced $518 million from the three national distributors against the up to $417.9 million the national deal would have paid the State.

How many opioid pills did Albertsons dispense in Washington?

The Attorney General's Office alleges more than 641 million prescription opioid pills between 2006 and 2022, including over 6.5 million prescriptions filled with red flags of diversion that were never resolved.

What happens next in the Washington Albertsons opioid case?

Judge Helson issues findings of fact and conclusions of law; post-trial motions follow; and any appeal goes to the Washington Court of Appeals, where the factual findings get deferential substantial-evidence review and the legal conclusions, including the abatement remedy, get de novo review.

How much has Washington recovered from opioid litigation so far?

The Attorney General's Office has reported opioid recoveries including $518 million from the three national distributors, $183 million from Purdue Pharma, $47.5 million from Kroger and $13.5 million from McKinsey, with the Albertsons claim still undecided.